Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
31
YBGJ Quote, Financials, Valuation and Earnings
Last price:
$0.0136
Seasonality move
:
100.08%
Day range:
$0.0136 - $0.0136
52-week range:
$0.0079 - $0.1776
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.99x
P/B ratio:
--
Volume:
--
Avg. volume:
32.6K
1-year change:
-72.8%
Market cap:
$2.3M
Revenue:
$3.5K
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
$0.0136 | -- | $2.3M | -- | $0.00 | 0% | 12.99x |
|
ADAG
Adagene, Inc.
|
$1.67 | $9.22 | $78.7M | -- | $0.00 | 0% | 751.59x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.87 | $4.00 | $17.9M | -- | $0.00 | 0% | 0.51x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.53 | -- | $5M | -- | $0.00 | 0% | 1.23x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.77 | $49.49 | $2B | -- | $0.00 | 0% | 4.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-9.09% | 0.108 | 5.91% | 0.05x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-$43.6K | -$310.1K | -- | -- | -11737.99% | -$359.1K |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Yubo International Biotech Ltd. vs. Competitors
-
Which has Higher Returns YBGJ or ADAG?
Adagene, Inc. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of --. Yubo International Biotech Ltd.'s return on equity of -- beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About YBGJ or ADAG?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 452.35%. Given that Adagene, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe Adagene, Inc. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is YBGJ or ADAG More Risky?
Yubo International Biotech Ltd. has a beta of 0.750, which suggesting that the stock is 25.002% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock YBGJ or ADAG?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or ADAG?
Yubo International Biotech Ltd. quarterly revenues are --, which are larger than Adagene, Inc. quarterly revenues of --. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than Adagene, Inc.'s net income of --. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 751.59x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K ADAGAdagene, Inc.751.59x -- -- --
-
Which has Higher Returns YBGJ or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of -353.92%. Yubo International Biotech Ltd.'s return on equity of -- beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About YBGJ or CASI?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 359.77%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is YBGJ or CASI More Risky?
Yubo International Biotech Ltd. has a beta of 0.750, which suggesting that the stock is 25.002% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock YBGJ or CASI?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or CASI?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 0.51x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K CASICASI Pharmaceuticals, Inc.0.51x -- $3.1M -$10.9M
-
Which has Higher Returns YBGJ or CPHI?
China Pharma Holdings, Inc. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of -86.16%. Yubo International Biotech Ltd.'s return on equity of -- beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About YBGJ or CPHI?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Yubo International Biotech Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Yubo International Biotech Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is YBGJ or CPHI More Risky?
Yubo International Biotech Ltd. has a beta of 0.750, which suggesting that the stock is 25.002% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock YBGJ or CPHI?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or CPHI?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 1.23x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K CPHIChina Pharma Holdings, Inc.1.23x -- $756.2K -$651.5K
-
Which has Higher Returns YBGJ or SVA?
Sinovac Biotech Ltd. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of --. Yubo International Biotech Ltd.'s return on equity of -- beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About YBGJ or SVA?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Yubo International Biotech Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Yubo International Biotech Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is YBGJ or SVA More Risky?
Yubo International Biotech Ltd. has a beta of 0.750, which suggesting that the stock is 25.002% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock YBGJ or SVA?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or SVA?
Yubo International Biotech Ltd. quarterly revenues are --, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns YBGJ or ZLAB?
Zai Lab Ltd. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of -30.98%. Yubo International Biotech Ltd.'s return on equity of -- beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About YBGJ or ZLAB?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 178.49%. Given that Zai Lab Ltd. has higher upside potential than Yubo International Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is YBGJ or ZLAB More Risky?
Yubo International Biotech Ltd. has a beta of 0.750, which suggesting that the stock is 25.002% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock YBGJ or ZLAB?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or ZLAB?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 4.32x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K ZLABZai Lab Ltd.4.32x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
42
OKLO alert for Dec 16
Oklo, Inc. [OKLO] is down 5.81% over the past day.
Sell
48
SEI alert for Dec 16
Solaris Energy Infrastructure, Inc. [SEI] is down 5.3% over the past day.
Sell
50
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 21.85% over the past day.
